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Abstract
Background: Electrical stimulation of central nervous system areas with surgically implanted stimulators has been
shown to result in pain relief. To avoid the risks and side effects of surgery, transcranial direct current stimulation is
an option to electrically stimulate the motor cortex through the skull. Previous research has shown that transcranial
direct current stimulation relieves pain in patients with fibromyalgia, chronic neuropathic pain and chronic pelvic
pain. Evidence indicates that the method is pain free, safe and inexpensive.
Methods/Design: A randomised controlled trial has been designed to evaluate the effect of transcranial direct
current stimulation over the motor cortex for pain reduction in patients with chronic low back pain. It will also
investigate whether transcranial direct current stimulation as a prior treatment enhances the symptom reduction
achieved by a cognitive-behavioural group intervention. Participants will be randomised to receive a series of 5
days of transcranial direct current stimulation (2 mA, 20 mins) or 20 mins of sham stimulation; followed by a
cognitive-behavioural group programme. The primary outcome parameters will measure pain (Visual Analog Scale)
and disability (Oswestry Disability Index). Secondary outcome parameters will include the Fear Avoidance Beliefs
Questionnaire, the Funktionsfragebogen Hannover (perceived function), Hospital Anxiety Depression Scale,
bothersomeness and Health Related Quality of Life (SF 36), as well as Patient-Perceived Satisfactory Improvement.
Assessments will take place immediately prior to the first application of transcranial direct current stimulation or
sham, after 5 consecutive days of stimulation, immediately after the cognitive-behavioural group programme and
at 4 weeks, 12 weeks and 24 weeks follow-up.
Discussion: This trial will help to determine, whether transcranial direct current stimulation is an effective
treatment for patients with chronic low back pain and whether it can further enhance the effects of a cognitive
behavioural pain management programme. Trial registration: Current Controlled Trials ISRCTN89874874.
1. Background
A literature review [1] on the epidemiology and eco-
nomic burden of non-specific chronic low back pain
reported estimates of prevalence ranging from 6% to
11%. In a cross-sectional survey with 9267 respondents,
average total back pain costs per patient per year in
Germany have been reported as €1322 [2]. Chronic low
back pain (CLBP) seems to account for the majority of
these expenses, with annual direct costs of > €7000 per
patient [1].
Imaging studies have revealed that pain is accompa-
nied by an extensive reorganisation of the brain.
Changes in chronic back pain patients are structural
[3,4] and functional [5] and reversible if the pain sub-
sides [6-8].
If a chronic pain conditions is regarded as non-specific
[9] and does not provide a peripheral tissue target for
treatment, the medical treatment approach needs to be
directed towards altering these central mechanisms by e.
g. prescribing opioids and antidepressants. Surgical
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tors in the brain. Deep brain stimulation [10-12], and
motor cortex stimulation [13,14] have demonstrated
pain reduction.
Transcranial direct current stimulation (tDCS) is a
non-invasive alternative that applies weak electrical cur-
rents (1-2 mA) through the skull to modulate the activ-
ity of neurons in the brain [15].
A current systematic review of the literature (Luedtke
et al., Clin. J. Pain, accepted) concluded that anodal
tDCS had a pain reducing effect in patients with chronic
pain due to spinal cord injury [16,17], fibromyalgia
[18,19], chronic pelvic pain [20], multiple sclerosis [21]
and various chronic pain conditions [22,23] when
applied with an intensity of 1-2 mA over the motor cor-
tex for 20 minutes on a minimum of 2 consecutive days.
However, the level of evidence was rated as “low”. A risk
of bias assessment of the 8 published trials showed that
only one trial was of an overall low risk of bias [21].
Four trials met the minimum criteria for the inclusion
in the meta-analysis of the results [16,18,21,23].
Although effects for pain were reported as statistically
significant across all trials, the pooled effect of -2.29
with a 95% confidence interval of -3.5 to -1.08 only just
reached minimal clinically important difference
recommendations.
A trial with high methodological quality is needed to
determine whether tDCS is effective in the reduction of
pain in chronic pain patients.
This trial will evaluate the effect of tDCS on pain and
disability of patients with non-specific CLBP and investi-
gate whether tDCS as a prior treatment enhances the
symptom reduction achieved by a cognitive-behavioural
group intervention.
2. Methods/Design
2.1 Design
Double-blind single-centre randomised controlled trial
with two study arms (real and sham stimulation) (Figure 1).
Participants will be allocated to groups (real or sham
tDCS) using computer generated randomisation lists,
stratified for high (51-100) and low (20-50) average pain
intensities over the past 24 hours. Block randomisation
(blocks of 20) was chosen to allow for equal numbers in
each group at regular time intervals.
Allocation concealment and blinding (patient and
therapist providing the intervention) is secured, since
the randomisation lists consist of 70 different number
codes for each group. Following consent at recruitment,
participants will be given the next available code from
the randomisation list. The stimulation code will be
entered into the tDCS device to initialise the stimulation
procedure. According to the entered code the device
produces an active or a sham stimulation paradigm.
Only the independent researcher (CW) will have access
to the list that unblinds the allocation to either tDCS or
sham stimulation group.
The stimulation period is followed by a four week
cognitive-behavioural group therapy.
2.2 Participants
Patients will be recruited and treated at a back pain
clinic in North Germany.
Patients will be eligible if they satisfy the following cri-
teria:
￿ Aged 18 - 65 years
￿ Categorised as suitable for a pain management
programme
￿ Have non-specific CLBP
◦ with a minimum of 3 months of low back pain
without any relevant ongoing pathologies such as
acute disc prolapse, acute inflammation, bone
fractures, spondylolisthesis or general health
restrictions that require medical attention
￿ Are waiting to attend a cognitive-behavioural
group programme at a back pain clinic in North
Germany.
￿ Provide written consent
Potential participants will be excluded if they have any
of the following:
￿ Other chronic pain syndromes
￿ spinal surgery in the past 6 month
Figure 1 Trial design.
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￿ Psychiatric disease
￿ Does not understand German
￿ Pregnant or likely to become pregnant during the
trial
￿ Alcohol-, drug-, medication abuse
Medication intake is not listed as an exclusion criter-
ion but type and dosage of medication will be recorded
and any change in medication documented.
2.3 Interventions
tDCS
tDCS is produced by a battery driven small stimulator
box and is applied to the skull via sponge electrodes.
The equipment is portable and of relatively low cost.
Application is easy and safe [24,25]. Across reported
trials on tDCS, authors have not observed any serious
adverse effects. Side effects have included mild burning
or tingling at the site of stimulation, headaches and
tiredness [24,26].
All participants will receive 20 mins of anodal tDCS
(anode placed over left motor cortex, reference electrode
supraorbital on right side) with an intensity of 2 mA, on
5 consecutive days. This dosage has been identified in a
systematic review of the current available evidence as
the stimulation parameters used in the majority of trials
(Luedtke et al., Clin. J. Pain, accepted). Large size (35
cm
2) sponge electrodes, soaked in a saline solution will
be placed over the stimulation sites and held in place by
an elastic bandage. The anode (positively charged elec-
trode) will be placed over the left primary motor cortex
(M1), while the cathode (negatively charged electrode)
will be placed above the right eyebrow. This electrode
arrangement has been shown to induce excitability
changes in the primary motor cortex [27] and has been
used in previous trials on tDCS for the relief of chronic
pain [16-23]. The participant will be positioned in
supine with legs elevated, during the stimulation.
To accurately determine the site of stimulation, single-
pulse magnetic stimuli (TMS) will be applied over the
motor cortex on the left side of the skull, until a twitch-
ing of the right index finger is observed.
Control intervention
An identical procedure will be used for the sham stimu-
lation, but the DC stimulator will not deliver an active
stimulation paradigm.
The sham paradigm initially produces a direct current,
but switches off automatically after 30 seconds. Partici-
pants perceive a tingling sensation identical to that per-
ceived during the real stimulation. This short
stimulation does not result in any neurophysiological
changes. The method has been shown to be a reliable
placebo condition [28]. However, recent studies applying
2 mA stimulations have stated that blinding at this
intensity may be less reliable [21]. Therefore blinding
will be assessed by asking the participant after the sti-
mulation which mode of stimulation he believes he has
received.
Cognitive-behavioural group programme
This pain management programme is the standard care
for patients at the back pain clinic involved in the
study. The effectiveness of interdisciplinary group pro-
grammes for the treatment of non-specific CLBP has
been demonstrated by a number of publications
[29-31]. A maximum of 9 patients per group will
receive physically challenging sessions, such as cardio-
vascular exercises and machine assisted muscle
strength training, specific muscle stabilisation exercises
for the trunk muscles, as well as information sessions
on the neurophysiology of pain, pain coping strategies
and relaxation classes. Individual sessions can be
added in the case of specific needs, such as acute addi-
tional pain that limits the capability to exercise, or bio-
feedback sessions if a patient finds it impossible to
relax in the group sessions. Patients will attend 5
hours of therapy daily (from Monday to Friday) as
outpatients.
The programme will be delivered by an interdisciplin-
ary team of orthopaedic consultants, physiotherapists,
psychologists and sports therapists who deliver this pro-
gramme routinely to patients at the clinic.
2.4. Outcome measures
Primary outcome measures
tDCS and the cognitive-behavioural group programme
aim to influence different factors associated with non-
specific CLBP. While tDCS is believed to directly influ-
ence pain processing within the central nervous system,
the cognitive-behavioural programme is targeting dis-
ability, beliefs and other psychosocial aspects of the pain
experience. Therefore, two primary outcome measures
will be used to assess the effect of tDCS as well as of
the cognitive-behavioural group programme:
￿ Pain: Visual analogue (VAS 0-100) or numerical
rating scale (NRS 0-10) over the past 24 hours. 0
indicates no pain and 100 or 10 indicates the worst
imaginable pain.
VAS was used in previous trials on tDCS for the
relief of chronic pain [16,18,21]. Minimum clinically
i m p o r t a n tc h a n g ef o rv i s u a lu n dn u m e r i c a lp a i n
scales in chronic pain patients has been described as
15 on a 0-100 VAS or 1.5 on a 0-10 NRS [32] or as
high as 2.4 in a recent publication [33].
￿ Disability: Oswestry Disability Index [34]. The
maximum score is 50 points with a high score indi-
cating a high level of disability.
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clinically important change in Oswestry Disability
index has been proposed as 10 points [32].
Secondary outcome parameters
￿ Patient-perceived satisfactory improvement
(PPSI): Participants’ perceived global rating of over-
all change (from baseline)w i l lb er e c o r d e do na5 -
point Likert-type scale (1 = much worse, 2 = slightly
worse, 3 = no change, 4 = slightly better, 5 = much
better) [36]. This measurement is a global indicator
for change.
￿ Bothersomeness: A second global score that will
be used is “bothersomeness”. This single question
("how bothersome is your pain today?”)t o o lg i v e s5
answering options: “not at all,”“ slightly,”“ moder-
ately,”“ very much,” and “extremely” [37].
￿ General health and health-related quality of life:
S F3 6h a sb e e nw i d e l yu s e di ns t u d yp o p u l a t i o n s
with chronic pain [38-40]. It has been translated and
validated into German [41].
￿ Perceived restriction of function: The Funktions-
fragebogen Hannover (FfbH-R) consists of 12 items
that ask about the patient’s capacity to perform daily
life activities. It has been designed to reflect the lim-
itations, a back pain patient may typically experience.
The answers are rated in a 3 point scale ("no, can’t
perform activity”, “yes, with difficulties”, “yes”).
Validity and reliability has been established [42].
￿ Fear avoidance beliefs: Fear avoidance beliefs
questionnaire (FABQ) developed by Waddell et al.
[43,44] translated into German [44] and evaluated
for its psychometric properties [45]. Fear avoidance
beliefs has been strongly associated with chronic
back pain in the past [46] although its role has
recently been questioned [47]. Since patients with a
high level of fear avoidance may respond differently
to the intervention, it is included in this study as a
secondary outcome parameter.
￿ Anxiety and Depression: Hospital anxiety and
depression scale (HADS) [48]. Analog to fear avoid-
ance beliefs, depression may hinder the effectiveness
of the intervention and needs to be documented for
the purpose of this trial.
2.5 Sample size
The sample size calculation was based on published
minimum clinically relevant change recommendations of
15 mm on a 0-100 mm VAS [32] and 8 points for the
ODI [33]. Standard deviations were taken from a pre-
vious publication on a comparable study population
[49]. With 90% power and a = .01 and anticipated
drop-out rates of 10% during the intervention phase and
15% between intervention and final follow-up, the
required sample size was calculated as 135.
2.6 Data analysis
Data will be digitalised from the paper version (source
data) into Microsoft excel spreadsheets by a blinded
investigator.
Data analysis will be conducted using SPSS 18 for
Apple Macintosh. The primary analysis will use a gen-
eral linear model to compare between-group effects on
the primary outcome measure, at 4 weeks, 12 weeks and
24 weeks follow-up, with baseline values as covariate.
Similar analyses will be conducted on appropriate sec-
ondary outcomes, or non-parametric tests as appropriate
(e.g. on PPSI).
2.7 Ethical aspects
Conduct of the study will be in accordance with the
Declaration of Helsinki [50]. The project has been
approved by the ethics committee of the Ärztekammer
Hamburg on 04.01.2010 (responsible body for studies
conducted on patients in the region of Hamburg). Ethi-
cal approval and was provided by the university ethics
committee at the University of Birmingham.
3 Discussion
The proposed study presents the first high quality ran-
domised controlled trial on tDCS for the reduction of
chronic pain. As identified in a recently published
Cochrane review [51] and a systematic review and
metaanalysis conducted by our group (Luedtke et al.,
Clin. J. Pain, accepted), only 8 studies have investigated
tDCS for chronic pain reduction [16-23]. None of
these was adequately powered to allow valid conclu-
sions on it’s effectiveness. Additional risk of bias was
introduced by methodological issues, such as invalid
randomisation procedures and unclear blinding, lead-
ing to a grading of the current level of evidence as
“low” (Luedtke et al., Clin. J. Pain, accepted) according
to the GRADE system [52]. Computer generated ran-
domisation lists and a tDCS device that produces pre-
programmed stimulation paradigms (verum and sham)
initialised by 5 digit number codes, will address these
issues in the proposed study. The sample size estima-
tion ensures adequate power (90%) to allow valid con-
clusions regarding the effectiveness of tDCS on the
two primary outcome parameters pain intensity (VAS)
and disability (ODI).
Chronic low back pain patients have been included in
two of the existing trials on various chronic pain condi-
tions [22,23] but no study has exclusively focused on
this patient group. With the high prevalence of low
back pain and the socioeconomic burden of chronic
pain, there is a demand for effective, safe, non-invasive
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group.
The choice of outcome parameters was based on the
review of previous publications on comparable study
populations/interventions. A range of identified mea-
surement tools was monitored over a 3 month period in
the back pain clinic. These included the Short Form
McGill Pain Questionnaire [53], the Visual Analog
Scale, the Roland Morris Disability Questionnaire [54]
and the Oswestry Disability Index [34]. This monitoring
p h a s es h o w e dt h a tt h eV i s u a lA n a l o gS c a l ea n dt h e
Oswestry Disability Index had the best responsiveness
and the least ceiling effects in the anticipated target
population.
However, the study is limited to investigate the short
term effects of tDCS and the combination of tDCS and
a cognitive-behavioural group programme. Since all
patients will receive the group programme following the
stimulation period, no long term effects of tDCS alone
can be measured. The group programme is currently
the standard care for patients attending the back pain
clinic and ethical as well as health insurance reasons
required that all patients receive the group programme
as soon as possible. It was therefore not feasible to
include a third group receiving tDCS alone or to post-
pone the group programme until long term measure-
ments were taken.
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